Este estudo demonstrou que indivíduos mais velhos, que ingerem bebida alcoólica e são diabéticos, de forma independente, apresentam graus mais avançados de fibrose hepática, entre portadores da infecção crônica pelo HCV. Desse modo, é de grande importância identificar indivíduos portadores de diabetes, infectados pelo HCV para que esta infecção seja tratada, o vírus erradicado e ocorra melhora do prognóstico da doença.
REFERÊNCIAS
ADINOLFI L, E., et al. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. International Journal of Molecular Sciences. v. 17, n. 6, p. 803, 2016.
ALTER, M. Epidemiology of hepatitis C virus infection. World Journal of Gastroenterology, v. 13, n. 17, p. 2436–2441, 2007.
AMERICAN DIABETES ASSOCIATION. Classification and diagnosis of diabetes. Diabetes Care, v. 38, n. suppl 1, p. S8–S16, 2015.
ANTONELLI, A. et al. Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes, v. 5, n. 5, p. 586–600, 2014.
BERTOT,L. C.; ADAMS LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. v. 17, n. 5, p. 774, 2016.
BRASIL. Ministério da Saúde. Hepatites virais no Brasil: situação, ações e agenda. Departamento de DST, Aids e Hepatites Virais. Brasília, Secretaria de Vigilância em Saúde, 2010.
BRASIL. Ministério da Saúde. Protocolo Clínico e Terapêutico de tratamento de hepatite C. Brasília: MS, 2015.
BALLESTRI, S. et al. Type 2 diabetes in non-alcoholic fatty liver disease and hepatitis c virus infection-liver: The "Musketeer" in the spotlight. International Journal of Molecular Sciences, v. 17, n. 3, p. 1–25, 2016.
BEDOSSA, P.; POYNARD, T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology (Baltimore, Md.), v. 24, n. 2, p. 289–93, 1996.
CASTERA, L. et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology, v. 128, n. 2, p. 343–350, 2005.
CAMERON F. J.; WHERRETT, D. K, Care of diabetes in children and adolescents: Controversies, changes, and consensus. Lancet. v. 385; p. 2096–2106, 2015.
CAMPIOTTO, S. et al. Geographic distribution of hepatitis C virus genotypes in Brazil. Brazilian Journal of Medical and Biological Research, v. 38, n. 1, p. 41–49, 2005.
CHAN, J. Hepatitis CDisease-a-Month, 2014.
CHAYAMA, K.; HAYES, C. N. Hepatitis C virus: How genetic variability affects pathobiology of disease. Journal of Gastroenterology and Hepatology (Australia), v. 26, n. suppl 1, p. 83-95, 2011.
CHEN, S. L.; MORGAN, T. R. The Natural History of Hepatitis C Virus (HCV) Infection. Int J Med Sci. v. 3, n. 2, p. 47–52, 2006.
CHENG, F. K. F.; TORRES, D. M.; HARRISON, S. A. Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: Still important in the era of direct acting antiviral therapy? Journal of Viral Hepatitis, v. 21, n. 1, p. 1–8, 2014.
CHOO, Q. L. et al. Isolation of a cDNA clone derived from a blood-borne non-A, non- B viral hepatitis genome. Science, v. 244, n. 4902, p. 359 LP-362, 1989.
COX, A. L. et al. Rare birds in North America: Acute Hepatitis C Cohorts. Gastroenterology, v. 136, p. 26-33, 2009.
DYAL, H. K. et al. Concurrent Obesity, Diabetes, and Steatosis Increase Risk of Advanced Fibrosis Among HCV Patients: A Systematic Review. Digestive Diseases and Sciences, v. 60, n. 9, p. 2813–2824, 2015.
with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol. v. 8; p. 458– 462, 2010.
FERREIRA, A. S. P. et al. Acute hepatitis C in Brazil: results of a national survey. J Med Virol. v. 83, p. 1738–1743, 2011.
FOCACCIA, R. et al. Demographic and anthropometrical analysis and genotype distribution of chronic hepatitis C patients treated in public and private reference centers in Brazil. The Brazilian journal of infectious diseases, v. 8, n. 5, p. 348–55, 2004.
GOH, G. B.-B. et al. Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. BBA Clinical, v. 3, p. 141–145, 2015.
GONDEAU, C; PAGEAUX, G. P.; LAR, D. Hepatitis C virus infection: Are there still specific problems with genotype 3? World J Gastroenterol. v. 21, n. 42, p. 12101- 12113, 2015.
GOWER, E. et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of Hepatology, v. 61, n. 1, p. S45–S57, 2014.
HASSAN, K. et al. Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic. World Journal of Gastroenterology, v. 20, n. 34, p. 12082–12101, 2014.
HAMAGUCHI, E. et al. Histological course of nonalcoholic fatty liver disease in Japanese patients: Tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care. v. 33, p. 284–286, 2010.
HELLER, T.; REHERMANN, B. Acute hepatitis C: a multifaceted disease. Seminars in liver disease. v. 25, n. 1, p. 7-17, 2005.
Hepatitis C Patients With .New-Onset Diabetes: A Nationwide Cohort Study. Hepatology. v. 60; n. 3; p. 807-814, 2014.
INZUCCHI, S. E. Clinical practice. Diagnosis of diabetes. New England Journal of Medicine. v. 367; p. 542–550, 2012.
JACOBSON, I. et al. Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options. N Engl J Med, v. 368, n. 20, p. 1867–1877, 2013.
JHA, D. K. et al. Association of type II diabetes mellitus with hepatocellular carcinoma occurrence—a case control study from Kathmandu Valley. Asian Pacific journal of cancer prevention, v. 13, n. 10, p. 5097-5099, 2012.
KANWAL, F. et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology, v. 60, n. 1, p. 98–105, 2014.
KAWAGUCHI, Y.; MIZUTA, T. Interaction between hepatitis C virus and metabolic factors. World Journal of Gastroenterology, v. 20, n. 11, p. 2888–2901, 2014.
KERSHENOBICH, D. et al. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver International, v. 31, n. suppl. 2, p. 18–29, 2011.
KNOBLER, H.; MALNICK, S. Hepatitis C and insulin action: An intimate relationship. World Journal of Hepatology, v. 8, n. 2, p. 131–138, 2016.
KRALJ, D. et al. Hepatitis C Virus, Insulin Resistance, and Steatosis. Journal of Clinical and Translational Hepatology, v. 4, n. 1, p. 66–75, 2016.
KRETZER, I. F. et al. Hepatitis C worldwide and in Brazil: Silent epidemic - Data on disease including incidence, transmission, prevention, and treatment. Scientific World Journal, v. 2014, 2014.
LAVANCHY, D. The global burden of hepatitis C. Liver International, v. 29, n. suppl 1, p. 74-81, 2009.
LAWITZ, E. et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med, v. 368, n. 20, p. 1878–1887, 2013.
LEANDRO, G. et al. Relationship Between Steatosis, Inflammation, and Fibrosis in Chronic Hepatitis C: A Meta-Analysis of Individual Patient Data. Gastroenterology, v. 130, n. 6, p. 1636–1642, 2006.
LEE, M.-H. et al. Epidemiology and natural history of hepatitis C virus infection. World journal of gastroenterology : WJG, v. 20, n. 28, p. 9270–80, 2014.
LONARDO, A. et al. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Dig. Liver Dis. v. 47; p. 181–190, 2015a.
LONARDO, A. et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Digestive and Liver Disease, v. 47, n. 12, p. 997–1006, 2015b.
LONARDO, A. et al. Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen. World J Gastroenterol. v. 20(23); p. 7089-7103, 2014.
LINGALA, S.; GHANY, M. G. Natural History of Hepatitis C. Gastroenterology Clinics of North America, v. 44, n. 4, p. 717–734, 2015.
MANGIA, A.; RIPOLI, M. Insulin resistance, steatosis and hepatitis C virus. Hepatology International, v. 7, n. 2013, p. 1–8, 2013.
virus acquisition in Spain. Journal of Hepatology, v. 48, n. 1, p. 20–27, 2008.
MILNER, K.-L. et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology, v. 138, n. 3, p. 932-41–3, 2010.
MOTA, M. et al. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism clinical and experimental. v. 65, n. 8, p. 1049-1061, 2016.
MOUCARI, R. et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. v. 134, n. 2, p. 416-423, 2008.
NASCIMBENI, F. et al. From NAFLD in clinical practice to answers from guidelines. Journal of Hepatology, v. 59, n. 4, p. 859–871, 2013.
NEGRO, F. Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases. Journal of Hepatology, v. 61, n. 1, p. S69–S78, 2014.
OLIVEIRA, J. E. P. DE; VENCIO, S. Diretrizes da Sociedade Brasileira de Diabetes 2015-2016. AC FARMACÊUTICA LTDA, p. 1–348, 2016.
SHIFFMAN, M. L.; GUNN, N. T. Impact of hepatitis C virus therapy on metabolism and public health. Liver International, v. 37, n. suppl 1, p. 13–18, 2017.
THRIFT, A. P.; EL-SERAG, H. B.; KANWAL, F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol, v. 14, n. 2, p. 122-132, 2017.
SANTANTONIO, T.; WIEGAND, J.; TILMAN GERLACH, J. Acute hepatitis C: Current status and remaining challenges. Journal of Hepatology, v. 49, n. 4, p. 625-633, 2008.
SZABÓ, E. et al. Viral hepatitis: new data on hepatitis C infection. Pathology oncology research , v. 9, n. 4, p. 215–221, 2003.
VANNI, E.; BUGIANESI, E.; SARACCO, G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality? Digestive and Liver Disease, v. 48, n. 2, p. 105–111, 2016.
WESTBROOK, R. H.; DUSHEIKO, G. Natural history of hepatitis C. Journal of Hepatology, v. 61, n. 1, p. S58–S68, 2014.
WORLD HEALTH ORGANIZATION. Prevention and Control of Viral, Hepatitis C key facts, Fact sheet no. 164, Geneva, Switzerland, 2017. Disponivel em: < http://www.who.int/mediacentre/factsheets/fs164/en/> acesso em maio de 2017.
ZHANG, J.; NGUYEN, D.; HU, K. Q. Chronic Hepatitis C Virus Infection: A Review of Current Direct-Acting Antiviral Treatment Strategies. North American Journal of Medical Sciences. v. 9, n. 2, p. 47-54, 2016.